LY3509754   Click here for help

GtoPdb Ligand ID: 13164

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: LY3509754 is an orally bioavailable, small molecule inhibitor of the proinflammatory cytokine IL-17A [1]. It was intended as an alternative to anti-IL-17A monoclonals for the treatment of psoriasis.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 132.58
Molecular weight 586.52
XLogP 3.41
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=NON=C1C(=O)N[C@@H](C2CCC(CC2)(F)F)C3=CN4C(=N3)C=C(C=N4)[C@@H](COC)N5C[C@@H](C(F)(F)F)NC5=O
Isomeric SMILES COC[C@@H](N1C[C@H](NC1=O)C(F)(F)F)C2=CC3=NC(=CN3N=C2)[C@@H](NC(=O)C4=NON=C4C)C5CCC(F)(F)CC5
InChI InChI=1S/C24H27F5N8O4/c1-12-19(35-41-34-12)21(38)33-20(13-3-5-23(25,26)6-4-13)15-9-37-18(31-15)7-14(8-30-37)16(11-40-2)36-10-17(24(27,28)29)32-22(36)39/h7-9,13,16-17,20H,3-6,10-11H2,1-2H3,(H,32,39)(H,33,38)/t16-,17+,20+/m1/s1
InChI Key MVWVCLAORBNXSD-UWVAXJGDSA-N
References
1. Datta-Mannan A, Regev A, Coutant DE, Dropsey AJ, Foster J, Jones S, Poorbaugh J, Schmitz C, Wang E, Woodman ME. (2024)
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study.
Clin Pharmacol Ther, [Epub ahead of print]. [PMID:38294091]